Table of Contents
Lung Cancer International
Volume 2012 (2012), Article ID 587424, 6 pages
http://dx.doi.org/10.1155/2012/587424
Research Article

Mutated KRAS Is an Independent Negative Prognostic Factor for Survival in NSCLC Stage III Disease Treated with High-Dose Radiotherapy

1Department of Oncology, Institute of Clinical Sciences, Sahlgrenska Academy at University of Gothenburg, 405 30 Gothenberg, Sweden
2Department of Oncology, Sahlgrenska University Hospital, 413 45 Gothenburg, Sweden
3Department of Pathology, Sahlgrenska University Hospital, 413 45 Gothenburg, Sweden
4Department of Cytogenetics, Sahlgrenska University Hospital, 413 45 Gothenburg, Sweden

Received 8 May 2012; Revised 10 July 2012; Accepted 14 August 2012

Academic Editor: Elisabeth Quoix

Copyright © 2012 A. Hallqvist et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

How to Cite this Article

A. Hallqvist, F. Enlund, C. Andersson, et al., “Mutated KRAS Is an Independent Negative Prognostic Factor for Survival in NSCLC Stage III Disease Treated with High-Dose Radiotherapy,” Lung Cancer International, vol. 2012, Article ID 587424, 6 pages, 2012. doi:10.1155/2012/587424